Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis

Clinical Study Evaluating the Effect of Pentoxifylline as Anti Inflammatory in Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints

Inclusion Criteria:

• Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) [9] i.e., 28 joints disease activity score (DAS 28) >2.6.
• Patients receiving the conventional DMARDs.
• Both sexes.
• Age range between 18and 70 years old

Exclusion Criteria:

• Patients with retinal or cerebral hemorrhage.
• Patients with renal and hepatic dysfunction.
• Patients with hypersensitivity to study medications.
• Pregnant and lactating females.
• Patients receiving biological or synthetic DMARDs